

Puma Biotechnology

Earnings Call

Commercial Update



March 2, 2023

nerlynx[®]
(neratinib) tablets




Forward-Looking Safe-Harbor Statement


This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.




PUMA's Pharmacy and Distributor Network



~\$54 Million net NERLYNX revenue in Q4'22




3,323 Ex-factory bottles were sold in Q4'22



Includes Commercial SP and SD







~64% of patients in Q4'22 started at a reduced dose* **



*Reduced dose defined as fewer than 6 pills per day

** FDA approved dose-escalation label supplement in June 2021

Rest of World Partnerships – Timelines

Region	Partner	Regulatory Approvals	Commercial Launches
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • Q2 2022 – Ext. Adj. in the Philippines • Q3 2022 – mBC in Singapore 	<ul style="list-style-type: none"> • 2020 – Singapore • Q2 2021 – Malaysia • Q3 / Q4 2021 – Brunei, New Zealand
Israel	 MEDISON Delivering Innovative Treatments	<ul style="list-style-type: none"> • 2020 – Approved in Ext. Adj. and mBC 	<ul style="list-style-type: none"> • 2020 – Launched
Canada	 Knight	<ul style="list-style-type: none"> • 2019 – Ext. Adj. approved • Q2 2021 – mBC approved 	<ul style="list-style-type: none"> • 2020 – Launched
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> • 2019 – Ext Adj in Argentina • 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina • 2021 – Ext Adj and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil • Q1 2022 – Ext. Adj. in Mexico • Q3 2022 – mBC in Ecuador 	<ul style="list-style-type: none"> • 2020 – Argentina • Q2 2021 – Chile • Q4 2021 – Peru • Q3 2022 – Brazil • Q1 2023 – Mexico
Europe Greater China Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<ul style="list-style-type: none"> • 2019 – EMA approval • 2019 – Ext. Adj. in Hong Kong • 2020 – Ext. Adj. in China, Taiwan • Q4 2021 – mBC in Taiwan • Q1 2023 – Ext Adj. in Morocco, South Africa 	<ul style="list-style-type: none"> • 2019 – Germany, UK, Austria • 2020 – Sweden, Finland, Scotland, Switzerland, Denmark • 2020 – Hong Kong • Q1 2021 – China (added to 2021 NRDL), Taiwan • Q1 2021 – Greece, Czech Republic • Q1 2022 – Ireland • Q3 2022 – Spain
South Korea	 BIXINK THERAPEUTICS	<ul style="list-style-type: none"> • Q4 2021 – Ext. Adj. in S. Korea 	<ul style="list-style-type: none"> • Q1 2022 – Launched

Puma Biotechnology

Earnings Call

Commercial Update



March 2, 2023

nerlynx[®]
(neratinib) tablets

